Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism
Hypothyroidism has been associated with atherosclerosis. The mechanisms of atherosclerosis in patients with thyroid failure remain controversial. Hypofibrinolysis might be a risk factor for thromboembolic disease in subclinical hypothyroidism (SH). We measured fibrinolytic activity in patients with...
Gespeichert in:
| Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2003-10, Vol.13 (10), p.971-977 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 977 |
|---|---|
| container_issue | 10 |
| container_start_page | 971 |
| container_title | Thyroid (New York, N.Y.) |
| container_volume | 13 |
| creator | Cantürk, Zeynep Çetinarslan, Berrin Tarkun, Ilhan Cantürk, Nuh Zafer Özden, Meltem Duman, Can |
| description | Hypothyroidism has been associated with atherosclerosis. The mechanisms of atherosclerosis in patients with thyroid failure remain controversial. Hypofibrinolysis might be a risk factor for thromboembolic
disease in subclinical hypothyroidism (SH). We measured fibrinolytic activity in patients with SH before and after levothyroxine (LT
4
) treatment and compared it to those of controls. We prospectively
included 35 patients with SH and 30 healthy controls. We treated patients with LT
4
until almost 6 months after the euthyroid state has been achieved. We measured fibrinogen, D-dimer, antithrombin
III (ATIII), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) activity, and factor VII. Clinical and anthropometric variables were recorded for both groups. We found increased
levels of fibrinogen, PAI-1, and factor VII and decreased levels of ATIII activity in patients compared to control (
p
< 0.001 and
p
< 0.05). Decrease of tPA was not significant (
p
> 0.05). At the end of the LT
4
treatment, significant decreases were determined in PAI-1 and factor VII (
p
< 0.05). In conclusion, our data suggest an important role of hypofibrinolytic
and hypercoagulable state on the development of atherosclerosis in patients with SH and beneficial effects of LT
4
treatment for decreasing the risk of atherosclerosis. |
| doi_str_mv | 10.1089/105072503322511382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71357024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71357024</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-e06ae046b81c5620aeb45aa44c24c8c92051f932573f279073ca0197d396393d3</originalsourceid><addsrcrecordid>eNqNkE9LxDAQxYMo7rr6BTxITt6q-dM07VFW1xUEwVU8lmmastG2WZNU6bc3yy548OJhmGH4vQfvIXROyRUleXFNiSCSCcI5Y4JSnrMDNKVCyKQgUh7GOwJJJLIJOvH-nRCa5ZIfowlNM0olkVPULHVnfYBgFF6NPugOg8eAn43_wAtQwTrcxJmDq439Aq-GFhy-NV6D19j0-M12usffJqzxaqhUa3qjoMXLcWPDenTW1MZ3p-iogdbrs_2eodfF3ct8mTw-3T_Mbx4TxdM8JJpkoEmaVTlVImMEdJUKgDRVLFW5KhgRtCk4E5I3TMaUXAGhhax5kfGC13yGLne-G2c_B-1D2RmvdNtCr-3gS0m5kISlEWQ7UDnrvdNNuXGmAzeWlJTbdsu_7UbRxd59qDpd_0r2dUYg3wHbN_R9a3SlXfiP9w-OrYWV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71357024</pqid></control><display><type>article</type><title>Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><creator>Cantürk, Zeynep ; Çetinarslan, Berrin ; Tarkun, Ilhan ; Cantürk, Nuh Zafer ; Özden, Meltem ; Duman, Can</creator><creatorcontrib>Cantürk, Zeynep ; Çetinarslan, Berrin ; Tarkun, Ilhan ; Cantürk, Nuh Zafer ; Özden, Meltem ; Duman, Can</creatorcontrib><description>Hypothyroidism has been associated with atherosclerosis. The mechanisms of atherosclerosis in patients with thyroid failure remain controversial. Hypofibrinolysis might be a risk factor for thromboembolic
disease in subclinical hypothyroidism (SH). We measured fibrinolytic activity in patients with SH before and after levothyroxine (LT
4
) treatment and compared it to those of controls. We prospectively
included 35 patients with SH and 30 healthy controls. We treated patients with LT
4
until almost 6 months after the euthyroid state has been achieved. We measured fibrinogen, D-dimer, antithrombin
III (ATIII), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) activity, and factor VII. Clinical and anthropometric variables were recorded for both groups. We found increased
levels of fibrinogen, PAI-1, and factor VII and decreased levels of ATIII activity in patients compared to control (
p
< 0.001 and
p
< 0.05). Decrease of tPA was not significant (
p
> 0.05). At the end of the LT
4
treatment, significant decreases were determined in PAI-1 and factor VII (
p
< 0.05). In conclusion, our data suggest an important role of hypofibrinolytic
and hypercoagulable state on the development of atherosclerosis in patients with SH and beneficial effects of LT
4
treatment for decreasing the risk of atherosclerosis.</description><identifier>ISSN: 1050-7256</identifier><identifier>EISSN: 1557-9077</identifier><identifier>DOI: 10.1089/105072503322511382</identifier><identifier>PMID: 14611707</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adult ; Blood Pressure ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - epidemiology ; Clinical Research Reports ; Female ; Fibrinolysis ; Hemostasis - physiology ; Humans ; Hypothyroidism - blood ; Hypothyroidism - complications ; Hypothyroidism - drug therapy ; Reference Values ; Risk Factors ; Thyroid Gland - physiology ; Thyroid Gland - physiopathology ; Thyrotropin - blood ; Thyroxine - blood ; Thyroxine - therapeutic use ; Triiodothyronine - blood</subject><ispartof>Thyroid (New York, N.Y.), 2003-10, Vol.13 (10), p.971-977</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-e06ae046b81c5620aeb45aa44c24c8c92051f932573f279073ca0197d396393d3</citedby><cites>FETCH-LOGICAL-c348t-e06ae046b81c5620aeb45aa44c24c8c92051f932573f279073ca0197d396393d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.liebertpub.com/doi/epdf/10.1089/105072503322511382$$EPDF$$P50$$Gmaryannliebert$$H</linktopdf><linktohtml>$$Uhttps://www.liebertpub.com/doi/full/10.1089/105072503322511382$$EHTML$$P50$$Gmaryannliebert$$H</linktohtml><link.rule.ids>315,782,786,3044,21730,27931,27932,55298,55310</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14611707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cantürk, Zeynep</creatorcontrib><creatorcontrib>Çetinarslan, Berrin</creatorcontrib><creatorcontrib>Tarkun, Ilhan</creatorcontrib><creatorcontrib>Cantürk, Nuh Zafer</creatorcontrib><creatorcontrib>Özden, Meltem</creatorcontrib><creatorcontrib>Duman, Can</creatorcontrib><title>Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism</title><title>Thyroid (New York, N.Y.)</title><addtitle>Thyroid</addtitle><description>Hypothyroidism has been associated with atherosclerosis. The mechanisms of atherosclerosis in patients with thyroid failure remain controversial. Hypofibrinolysis might be a risk factor for thromboembolic
disease in subclinical hypothyroidism (SH). We measured fibrinolytic activity in patients with SH before and after levothyroxine (LT
4
) treatment and compared it to those of controls. We prospectively
included 35 patients with SH and 30 healthy controls. We treated patients with LT
4
until almost 6 months after the euthyroid state has been achieved. We measured fibrinogen, D-dimer, antithrombin
III (ATIII), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) activity, and factor VII. Clinical and anthropometric variables were recorded for both groups. We found increased
levels of fibrinogen, PAI-1, and factor VII and decreased levels of ATIII activity in patients compared to control (
p
< 0.001 and
p
< 0.05). Decrease of tPA was not significant (
p
> 0.05). At the end of the LT
4
treatment, significant decreases were determined in PAI-1 and factor VII (
p
< 0.05). In conclusion, our data suggest an important role of hypofibrinolytic
and hypercoagulable state on the development of atherosclerosis in patients with SH and beneficial effects of LT
4
treatment for decreasing the risk of atherosclerosis.</description><subject>Adult</subject><subject>Blood Pressure</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Clinical Research Reports</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>Hemostasis - physiology</subject><subject>Humans</subject><subject>Hypothyroidism - blood</subject><subject>Hypothyroidism - complications</subject><subject>Hypothyroidism - drug therapy</subject><subject>Reference Values</subject><subject>Risk Factors</subject><subject>Thyroid Gland - physiology</subject><subject>Thyroid Gland - physiopathology</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine - blood</subject><subject>Thyroxine - therapeutic use</subject><subject>Triiodothyronine - blood</subject><issn>1050-7256</issn><issn>1557-9077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE9LxDAQxYMo7rr6BTxITt6q-dM07VFW1xUEwVU8lmmastG2WZNU6bc3yy548OJhmGH4vQfvIXROyRUleXFNiSCSCcI5Y4JSnrMDNKVCyKQgUh7GOwJJJLIJOvH-nRCa5ZIfowlNM0olkVPULHVnfYBgFF6NPugOg8eAn43_wAtQwTrcxJmDq439Aq-GFhy-NV6D19j0-M12usffJqzxaqhUa3qjoMXLcWPDenTW1MZ3p-iogdbrs_2eodfF3ct8mTw-3T_Mbx4TxdM8JJpkoEmaVTlVImMEdJUKgDRVLFW5KhgRtCk4E5I3TMaUXAGhhax5kfGC13yGLne-G2c_B-1D2RmvdNtCr-3gS0m5kISlEWQ7UDnrvdNNuXGmAzeWlJTbdsu_7UbRxd59qDpd_0r2dUYg3wHbN_R9a3SlXfiP9w-OrYWV</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Cantürk, Zeynep</creator><creator>Çetinarslan, Berrin</creator><creator>Tarkun, Ilhan</creator><creator>Cantürk, Nuh Zafer</creator><creator>Özden, Meltem</creator><creator>Duman, Can</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031001</creationdate><title>Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism</title><author>Cantürk, Zeynep ; Çetinarslan, Berrin ; Tarkun, Ilhan ; Cantürk, Nuh Zafer ; Özden, Meltem ; Duman, Can</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-e06ae046b81c5620aeb45aa44c24c8c92051f932573f279073ca0197d396393d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Blood Pressure</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Clinical Research Reports</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>Hemostasis - physiology</topic><topic>Humans</topic><topic>Hypothyroidism - blood</topic><topic>Hypothyroidism - complications</topic><topic>Hypothyroidism - drug therapy</topic><topic>Reference Values</topic><topic>Risk Factors</topic><topic>Thyroid Gland - physiology</topic><topic>Thyroid Gland - physiopathology</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine - blood</topic><topic>Thyroxine - therapeutic use</topic><topic>Triiodothyronine - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cantürk, Zeynep</creatorcontrib><creatorcontrib>Çetinarslan, Berrin</creatorcontrib><creatorcontrib>Tarkun, Ilhan</creatorcontrib><creatorcontrib>Cantürk, Nuh Zafer</creatorcontrib><creatorcontrib>Özden, Meltem</creatorcontrib><creatorcontrib>Duman, Can</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thyroid (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cantürk, Zeynep</au><au>Çetinarslan, Berrin</au><au>Tarkun, Ilhan</au><au>Cantürk, Nuh Zafer</au><au>Özden, Meltem</au><au>Duman, Can</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism</atitle><jtitle>Thyroid (New York, N.Y.)</jtitle><addtitle>Thyroid</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>13</volume><issue>10</issue><spage>971</spage><epage>977</epage><pages>971-977</pages><issn>1050-7256</issn><eissn>1557-9077</eissn><abstract>Hypothyroidism has been associated with atherosclerosis. The mechanisms of atherosclerosis in patients with thyroid failure remain controversial. Hypofibrinolysis might be a risk factor for thromboembolic
disease in subclinical hypothyroidism (SH). We measured fibrinolytic activity in patients with SH before and after levothyroxine (LT
4
) treatment and compared it to those of controls. We prospectively
included 35 patients with SH and 30 healthy controls. We treated patients with LT
4
until almost 6 months after the euthyroid state has been achieved. We measured fibrinogen, D-dimer, antithrombin
III (ATIII), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) activity, and factor VII. Clinical and anthropometric variables were recorded for both groups. We found increased
levels of fibrinogen, PAI-1, and factor VII and decreased levels of ATIII activity in patients compared to control (
p
< 0.001 and
p
< 0.05). Decrease of tPA was not significant (
p
> 0.05). At the end of the LT
4
treatment, significant decreases were determined in PAI-1 and factor VII (
p
< 0.05). In conclusion, our data suggest an important role of hypofibrinolytic
and hypercoagulable state on the development of atherosclerosis in patients with SH and beneficial effects of LT
4
treatment for decreasing the risk of atherosclerosis.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>14611707</pmid><doi>10.1089/105072503322511382</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-7256 |
| ispartof | Thyroid (New York, N.Y.), 2003-10, Vol.13 (10), p.971-977 |
| issn | 1050-7256 1557-9077 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71357024 |
| source | Mary Ann Liebert Online Subscription; MEDLINE |
| subjects | Adult Blood Pressure Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Clinical Research Reports Female Fibrinolysis Hemostasis - physiology Humans Hypothyroidism - blood Hypothyroidism - complications Hypothyroidism - drug therapy Reference Values Risk Factors Thyroid Gland - physiology Thyroid Gland - physiopathology Thyrotropin - blood Thyroxine - blood Thyroxine - therapeutic use Triiodothyronine - blood |
| title | Hemostatic System as a Risk Factor for Cardiovascular Disease in Women with Subclinical Hypothyroidism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T02%3A20%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemostatic%20System%20as%20a%20Risk%20Factor%20for%20Cardiovascular%20Disease%20in%20Women%20with%20Subclinical%20Hypothyroidism&rft.jtitle=Thyroid%20(New%20York,%20N.Y.)&rft.au=Cant%C3%BCrk,%20Zeynep&rft.date=2003-10-01&rft.volume=13&rft.issue=10&rft.spage=971&rft.epage=977&rft.pages=971-977&rft.issn=1050-7256&rft.eissn=1557-9077&rft_id=info:doi/10.1089/105072503322511382&rft_dat=%3Cproquest_cross%3E71357024%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71357024&rft_id=info:pmid/14611707&rfr_iscdi=true |